- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02243592
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To identify molecular indicators in malignant tissues from patients who were exceptional responders on clinical trials or standard systemic treatments using whole exome and/or targeted deep sequencing, as well as potentially other sequencing and other molecular characterization methods (if adequate tissue exists).
II. To explore associations between the identified molecular indicators and the putative mechanism of action of the treatment received by the patient.
III. To test the feasibility of identifying "exceptional responders", obtaining the relevant tumor and normal tissue and clinical data, and performing whole exome and/or targeted deep sequencing on these samples.
OUTLINE:
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted next generation sequencing (NGS) assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, messenger ribonucleic acid (RNA) (mRNA)-sequencing, micro (miRNA) sequencing, promoter methylation analysis, and single nucleotide polymorphism (SNP) analysis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Fresno, California, United States, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, United States, 94611
- Kaiser Permanente-Oakland
-
Richmond, California, United States, 94801
- Kaiser Permanente-Richmond
-
San Francisco, California, United States, 94158
- UCSF Medical Center-Mission Bay
-
Santa Clara, California, United States, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, United States, 95403
- Kaiser Permanente-Santa Rosa
-
Stockton, California, United States, 95210
- Kaiser Permanente-Stockton
-
Walnut Creek, California, United States, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- UCHealth University of Colorado Hospital
-
Fort Collins, Colorado, United States, 80524
- Poudre Valley Hospital
-
-
Connecticut
-
Greenwich, Connecticut, United States, 06830
- Greenwich Hospital
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, United States, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- Sibley Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
Columbus, Georgia, United States, 31904
- John B Amos Cancer Center
-
Valdosta, Georgia, United States, 31602
- South Georgia Medical Center/Pearlman Cancer Center
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60631
- Presence Resurrection Medical Center
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, United States, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, United States, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Peoria, Illinois, United States, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, United States, 62702
- Springfield Clinic
-
-
Iowa
-
Cedar Rapids, Iowa, United States, 52402
- Physicians' Clinic of Iowa PC
-
-
Maine
-
York, Maine, United States, 03909
- York Hospital
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- NCI - Center for Cancer Research
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- Saint Joseph Mercy Hospital
-
Brighton, Michigan, United States, 48114
- Saint Joseph Mercy Brighton
-
Detroit, Michigan, United States, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health at Butterworth Campus
-
Marquette, Michigan, United States, 49855
- UP Health System Marquette
-
Marquette, Michigan, United States, 49855
- UP Health System Hematology Oncology Marquette
-
Southfield, Michigan, United States, 48075
- Ascension Providence Hospitals - Southfield
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Saint Francis Medical Center
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63131
- Missouri Baptist Medical Center
-
Saint Louis, Missouri, United States, 63141
- Mercy Hospital Saint Louis
-
Springfield, Missouri, United States, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, United States, 65804
- Mercy Hospital Springfield
-
-
Montana
-
Great Falls, Montana, United States, 59405
- Benefis Healthcare- Sletten Cancer Institute
-
-
New Hampshire
-
Portsmouth, New Hampshire, United States, 03802
- Portsmouth Regional Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Sanford Roger Maris Cancer Center
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Riverside Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, United States, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, United States, 19460
- Phoenixville Hospital
-
West Chester, Pennsylvania, United States, 19380
- Chester County Hospital
-
West Reading, Pennsylvania, United States, 19611
- Reading Hospital
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, United States, 29605
- Prisma Health Cancer Institute - Butternut
-
Seneca, South Carolina, United States, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, United States, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Kingsport, Tennessee, United States, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, United States, 77030
- Ben Taub General Hospital
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Cancer Center
-
-
West Virginia
-
Martinsburg, West Virginia, United States, 25401
- WVUH-Berkely Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Carbone Cancer Center
-
Summit, Wisconsin, United States, 53066
- Aurora Medical Center in Summit
-
Waukesha, Wisconsin, United States, 53188
- UW Cancer Center at ProHealth Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Documented exceptional response, defined as patients meeting the following criteria:
- Complete response to a regimen in which complete response is expected in < 10% of similarly treated patients
- Partial response (PR) > 6 months in a regimen in which PRs > 6 months are expected in < 10% of patients with similar disease treated with same or similar regimen
Complete response (CR) or PR of unusual duration, such that the internal review committee considers it to be an exceptional response; examples below:
- PR of duration > 3 x the median expected PR duration (in cases where PR is expected in > 10% of patients with the same disease treated with the same regimen)
- CR or duration > 3 x the median expected CR duration (in cases where CR may be seen in > 10% of patients with same disease treated with same regimen)
- The observed duration of CR (or PR) is longer than expected for 90% of patients with same disease treated with same regimen
- Note: it is not required that the patient be enrolled on a clinical trial when the exceptional response was observed
- Reports of radiologic scans or other evidence documenting response will be submitted for review; cases where response is not assessable (e.g. adjuvant treatment) will not be eligible because the outcome can not be attributed to a specific treatment
- Treatment history must be available, for prior treatment and for the drug to which the exceptional response occurred
- Patient must meet consent criteria; this requires: (i) current exceptional responder (ER) consent by a living participant not lost to follow-up, (ii) prior consent for future research by a participant not known to be deceased, but lost to follow-up, or (iii) if patient is deceased and did not decline to participate in research at the time of tissue removal for any tissue that would be used in this study, then no consent is required
- Tumor sample available that meets study requirements
Required tumor samples MUST exist and be able to be submitted; investigators wishing to submit samples must not have made agreements that would prohibit the free use of data from such samples; the National Cancer Institute (NCI) will provide investigators with a letter for the collaborator amending their existing agreement to allow for the case to be submitted
- Tumor tissue from prior to administration of the drug to which the exceptional response occurred is required; ideally this sample will have been collected just prior to treatment, but other prior tissue will be considered; tissue may be fresh frozen or formalin-fixed paraffin embedded
- Tumor tissue amount must be at least a core biopsy, and meet minimum specimen requirements
- Encouraged: normal tissue sample: (optional): blood or other specimen source for germline sequencing
- The tumor samples and clinical data submitted to the Exceptional Responders Database in database in Genotypes and Phenotypes (dbGaP) will need to have appropriate agreements in place to allow for the submission; the Exceptional Responders Database can accept clinical data and samples from cases enrolled on a Cancer Therapy Evaluation Program (CTEP) sponsored clinical trial and cases that were not enrolled on any clinical trial; if the response occurred on a trial that was not CTEP-sponsored, there are existing agreements between the submitting site and the pharmaceutical company; if existing agreements do not allow for the submission of sample and clinical data, the NCI will provide the investigators with a letter that allows the tissue to be used for the exceptional responders study if signed by the appropriate collaborator; the letter modifies the existing agreement to include the CTEP Intellectual Property (IP) Option language that would allow the case to be submitted to the Exceptional Responders Database; if the existing agreement cannot be modified and the letter cannot be signed, the proposed case will not be accepted; Note: as stated above, the patient does not need to have been enrolled on a clinical trial to be eligible for the exceptional responders study
Exclusion Criteria:
- Patient's response did not meet criteria for an exceptional response
- Patient's treatment regimen is expected to lead to CR or durable PR in > 10% of patients
- Patient's duration of response is not > 3 x expected median length of response
- Response not evaluable or not able to be attributed to systemic treatment (e.g. adjuvant treatment)
- Patient refused consent for use of tissue for research activities included in the exceptional responders study
- Tumor sample from prior to the exceptional response is not available, or does not meet quality metrics
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ancillary-Correlative (molecular profiling)
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing.
Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
|
Undergo sequencing and SNP analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular features in tissue samples from patients who were exceptional responders
Time Frame: Baseline
|
The molecular features of the tumors in the patients will be discernible as distinct to the tumor by comparison to (i) samples from normal tissue in the same patient and (ii) databases of similar data for normal and other tumor types.
|
Baseline
|
Putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses
Time Frame: Baseline
|
The associations between identified molecular features and the putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses will be explored.
Statistical analyses will be primarily descriptive.
|
Baseline
|
Number of cases identified as potential exceptional responders
Time Frame: Baseline
|
Statistical analyses will be primarily descriptive.
|
Baseline
|
Percentage of identified potential cases confirmed to be exceptional responders
Time Frame: Baseline
|
Statistical analyses will be primarily descriptive.
|
Baseline
|
Percentage of confirmed exceptional responders for which adequate tissue with appropriate informed consent is acquired
Time Frame: Baseline
|
Statistical analyses will be primarily descriptive.
|
Baseline
|
Percentage of acquired cases with tissue for which at least the minimum molecular characterization is successfully obtained
Time Frame: Baseline
|
Statistical analyses will be primarily descriptive.
|
Baseline
|
Percentage of molecularly characterized cases for which a Molecular Characterization report identified (without reference to the drug received by the patient) at least one feature judged to have potential therapeutic relevance
Time Frame: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained.
For each such case, molecular data will be reviewed by an expert panel ("Panel") to identify interesting features.
All estimated proportions will be accompanied by exact 95% confidence intervals.
|
Baseline
|
Percentage of cases with >= 1 feature on Molecular Characterization report that was judged to have potential therapeutic relevance to the specific class of drug the patient actually received when the exceptional response was experienced
Time Frame: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained.
For each such case, molecular data will be reviewed by the Panel to identify interesting features.
All estimated proportions will be accompanied by exact 95% confidence intervals.
|
Baseline
|
Percentage of cases with >= 1 feature that correlates with the mechanism of action of the specific grant to which the exceptional response occurred that was found after further analyzing the molecular profile data for relevant molecular abnormalities
Time Frame: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained.
For each such case, molecular data will be reviewed by the Panel to identify interesting features.
All estimated proportions will be accompanied by exact 95% confidence intervals.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: S. P Ivy, National Cancer Institute (NCI)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2014-01585 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- UM1CA186704 (U.S. NIH Grant/Contract)
- 9671 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States